Niche markets and evidence assessment in transition: A critical review of proposed drug reforms

Medical Law Review

Volumn 22, Issue 2, 2014, Pages 200-220

  Gibson, Shannon G ^a   Lemmens, Trudo ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

ADVERTIZING; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; ECONOMICS; EUROPE; GOVERNMENT REGULATION; HEALTH CARE POLICY; HUMAN; LEGISLATION AND JURISPRUDENCE; PHARMACOGENETICS; REIMBURSEMENT;

ADVERTISING AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; DRUG INDUSTRY; EUROPE; GOVERNMENT REGULATION; HEALTH CARE REFORM; HUMANS; LEGISLATION, DRUG; ORPHAN DRUG PRODUCTION; PHARMACOGENETICS; PRESCRIPTION DRUGS; REIMBURSEMENT MECHANISMS;

EID: 84901627821     PISSN: 09670742     EISSN: 14643790     Source Type: Journal    
DOI: 10.1093/medlaw/fwu005     Document Type: Article

References (128)

1. Department of Health, 'The case for change-The Health and Social Care Act 2012' (Factsheet A2, last updated April 2012) accessed 10 March 2013.
2. Parliamentary Office of Science and Technology, 'Drug Pricing' (POSTnote 364) (2010) accessed 10 March 2014.
3. Office of Fair Trading, 'OFT Report Recommends Reform to UK Drug Pricing Scheme' (2007) accessed 10 March 2014.
4. National Institute for Health and Care Excellence, 'Nice "Central" to Value Based Pricing of Medicines' (2013) accessed 10 March 2014.
5. Parliamentary Office of Science and Technology, above, n 2, 1.
6. R Collier, 'Bye, Bye Blockbusters, Hello Niche Busters' (2011) 183 Can Med Assoc J 697, 697.
7. See, for example, J-P Garnier, 'Rebuilding the R&D Engine in Big Pharma' (2008) 86 Harv Bus Rev 69, 70;
8. DW Light and JR Lexchin, 'Pharmaceutical Research and Development: What Do We Get for All That Money?' (2012) 345 Brit Med J e4348, 4348.
9. JA DiMasi and HG Grabowski, 'The Cost of Biopharmaceutical R&D: Is Biotech Different?' (2007) 28 Man Dec Econ 469.
10. WN Hait, 'Forty Years of Translational Cancer Research' (2011) 1 Cancer Discov 383.
11. Collier, above, n 6, 697.
12. Light and Lexchin, above, n 7, 1.
13. B Munos, 'Lessons from 60 Years of Pharmaceutical Innovation' (2009) 8 Nat Rev Drug Discov 959.
14. Light and Lexchin, above, n 7, 1.
15. See, for example, the discussion by A Hollis, 'Me-too Drugs: Is There a Problem?' (2004) (brief note) accessed 10 March 2014.
16. SG Morgan, CM Cunningham, and MR Law, 'Drug Development: Innovation or Imitation Deficit?' (2012) 345 Brit Med J e5580.
17. Collier, above, n 6.
18. W Boon and E Moors, 'Exploring Emerging Technologies Using Metaphors: A Study of Orphan Drugs and Pharmacogenomics' (2008) 66 Soc Sci Med 1915.
19. Morgan and others, above, n 16.
20. J Woodcock, 'The Prospects for "Personalized Medicine" in Drug Development and Drug Therapy' (2007) 81 Clin Pharmacol & Ther 164, 167.
21. E Dolgin, 'Big Pharma Moves from "Blockbusters" to "Niche Busters"' (2010) 16 Nat Med 837, 837.
22. T Freeman, 'Orphan Drugs Big Potential in Small Disease States' (17 September 2012) Applied Clinical Trials Online accessed 10 March 2014.
23. JD Rockoff, 'Drug Makers See Profit Potential in Rare Diseases' Wall Street Journal (New York, 30 January 2013) accessed 10 March 2014.
24. JP Cohen, 'Overcoming Regulatory and Economic Challenges Facing Pharmacogenomics' (2012) 29 New Biotech 751, 751.
25. Personalized Medicine Coalition, 'Personalized Medicine by the Numbers' (2011) accessed 10 March 2014.
26. H Brody and DW Light, 'The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health' (2011) 101 Am J Public Health 399.
27. National Human Genome Research Institute, 'Frequently Asked Questions about Pharmacogenomics' (2011) accessed 10 March 2014.
28. Woodcock, above, n 20, 167.
29. Cohen, above, n 24.
30. MR Trusheim, ER Berndt, and FL Douglas, 'Stratified Medicine: Strategic and Economic Implications of Combining Drugs and Clinical Biomarkers' (2007) 6 Nat Rev Drug Discov 287.
31. Trusheim and others, above, n 33.
32. M Avery, 'Personalized Medicine and Rescuing "Unsafe" Drugs with Pharmacogenomics: A Regulatory Perspective' (2010) 65 Food Drug L J 37.
33. Trusheim and others, above, n 33.
34. Boon and Moors, above, n 18.
35. P Keeling, 'Personalized Medicine: The Absence of "Model-Changing" Financial Incentives' (2007) 4(1) Pers Med 73.
36. FiercePharma, 'Herceptin' (2012) accessed 10 March 2014.
37. A Pollack, 'Doctors Denounce Cancer Drug Prices of $100,000 a Year' New York Times (Los Angeles, 2013) accessed 10 March 2014.
38. Collier, above, n 6.
39. Cohen, above, n 24.
40. Experts in Chronic Myeloid Leukemia, 'Price of Drugs for Chronic Myeloid Leukemia (CML), Reflections of the Unsustainable Cancer Drug Prices: Perspective of CML Experts' (2013) 121 Blood 4439.
41. TR Coté, K Xu, and AR Pariser, 'Accelerating Orphan Drug Development' (2010) 9 Nat Rev Drug Discov 901.
42. The Committee for Orphan Medicinal Products and the European Medicines Agency Scientific Secretariat, 'European Regulation on Orphan Medicinal Products: 10 Years of Experience and Future Perspectives' (2011) 10 Nat Rev Drug Discov 341.
43. VG Koch, 'Incentivizing Utilization of Pharmacogenomics in Drug Development' (2012) 15 J Healthcare Law Policy 263.
44. Nuffield Council on Bioethics, 'Regulation and Public Policy' in Pharmacogenetics (Nuffield Council on Bioethics, London 2003).
45. D Loughnot, 'Potential Interactions of the Orphan Drug Act and Pharmacogenomics: A Flood of Orphan Drugs and Abuses?' (2005) 31 Am J Law Med 365.
46. Nuffield Council on Bioethics, above, n 51.
47. Based on a search of: Food and Drug Administration, 'Orphan Drug Designations and Approvals' accessed 10 March 2014;
48. A search of: European Commission, 'Register of not active Orphan Medicinal Products (alphabetical)' accessed 10 March 2014.
49. Based on a search of the FDA database, above, n 55.
50. Based on a search of the European Commission register, above, n 56.
51. M Herder, 'When Everyone is an Orphan: Against Adopting a US-style Orphan Drug Policy in Canada' (2013) 20 (4) Account Res 227.
52. Pharmaceuticals are subject to various quality requirements from both the EMA and the UK Medicines and Healthcare Products Regulatory Agency. See European Medicines Agency, 'Quality guidelines' accessed 10 March 2014;
53. Medicines and Healthcare Products Regulatory Agency, 'Inspection and standards' accessed 10 March 2014>.
54. T Lemmens, 'Pharmaceutical Knowledge Governance: A Human Rights Perspective' (2013) 41(1) J Law Med Ethics 163.
55. V Suvarna, 'Phase IV of Drug Development' (2010) 1(2) Perspect Clin Res 57.
56. SR Ahmad, 'Adverse Drug Event Monitoring at the Food and Drug Administration' (2003) 18 J Gen Intern Med 57.
57. M Wiktorowicz and others, 'Pharmacovigliance in Europe and North America: Divergent Approaches' (2012) 75 Soc Sci Med 165. A 2012 study revealed that around 11% of prescription drugs in Canada are prescribed for off-label use, while a similar study conducted in the USA in 2006 found that 21% of prescriptions were for off-label uses.
58. See T Eguale and others, 'Drug, Patient, and Physician Characteristics Associated with Off-label Prescribing in Primary Care' (2012) 172(10) Arch Intern Med 781;
59. DC Radley and others, 'Off-label Prescribing among Office-based Physicians' (2006) 166(9) Arch Intern Med 1021. A study conducted by McIntyre and colleagues in 2000 in the UK found that 10.5% of drugs prescribed to children by general practitioners were for off-label uses.
60. See J McIntyre and others, 'Unlicensed and Off Label Prescribing of Drugs in General Practice' (2000) 83 Arch Dis Child 498. A smaller study of psychiatrists in the UK found that 65% of 116 psychiatrists surveyed had prescribed drugs off-label.
61. See F Lowe-Ponsford and D Baldwin, 'Off-label Prescribing by Psychiatrists' (2000) 24 Psychiatrist 415.
62. CM Flood and P Dyke, 'The Data Divide Managing and Misalignment in Canada's Evidentiary Requirements for Drug Regulation and Funding' (2012) 45 UBC L Rev 283.
63. See Institute of Medicine, 'The Future of Drug Safety: Promoting and Protecting the Health of the Public' (2006) accessed 10 March 2014.
64. See Health Canada, 'Blueprint for Renewal: Transforming Canada's Approach to Regulating Health Products and Food' (2006) accessed 10 March 2014.
65. European Medicines Agency, 'Road Map to 2015: The European Medicines Agency's Contribution to Science, Medicines and Health' (16 December 2010) accessed 10 March 2014 at 21.
66. H-G Eichler and others, 'Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval' (2012) 91 Clin Pharmacol Ther 426, 428.
67. See International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 'Performance-Based Risk-Sharing Arrangements-Good Practices for Design, Implementation and Evaluation: An ISPOR Task Force Report' (Final Draft for Review) accessed 10 March 2014.
68. Parliamentary Office of Science and Technology, above, n 2.
69. See Health Canada, above, n 67, 30.
70. European Medicines Agency, 'Annual Renewal of Conditional Marketing Authorisations: Questions and Answers' accessed 10 March 2014.
71. European Medicines Agency, 'EMEA Concludes First Accelerated Assessment for a Medicine for Human Use' (2007) accessed 10 March 2014.
72. Boon and Moors, above, n 18.
73. A Owen and others, 'A New Model to Evaluate the Long-term Cost Effectiveness of Orphan and Highly Specialised Drugs Following Listing on the Australian Pharmaceutical Benefits Scheme: The Bosentan Patient Registry' (2008) 11 J Med Econ 235.
74. See 'Marketing Authorization under Exceptional Circumstances': European Medicines Agency, 'Questions and Answers on Presubmission Guidance' accessed 10 March 2014.
75. TJ Moore and CD Furberg, 'Development Times, Clinical Testing, Postmarket Follow-up, and Safety Risks for the New Drugs Approved by the US Food and Drug Administration The Class of 2008' (2013) JAMA Intern Med accessed 10 March 2014.
76. US Food and Drug Administration, 'Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products (Draft Guidance for Industry)' (2012) accessed 10 March 2014.
77. Cohen, above, n 24, 752.
78. O Wellman-Labadie and Y Zhou, 'The US Orphan Drug Act: Rare Disease Research Stimulator or Commercial Opportunity' (2010) 95 Health Policy 216, 225.
79. RA Bouchard and M Sawicka, 'The Mud and the Blood and the Beer: Canada's Progressive Licensing Framework for Drug Approval' (2009) 3 McGill J Law Health 49.
80. J Lexchin, 'New Drugs and Safety: What Happened to New Active Substances Approved Between 1985 and 2010?' (2012) 172 (21) Arch Intern Med 1680. A similar study in 2009 by Berlin found that where oncology drugs are approved under the accelerated approval or priority review channels offered by the FDA, drug labelling is revised significantly more frequently than the labelling for traditional drug products.
81. See RJ Berlin, 'Examination of the Relationship Between Oncology Drug Labeling Revision Frequency and FDA Product Categorization' (2009) 99(9) Am J Public Health 1693.
82. MA Hamburg and JM Sharfstein, 'The FDA as a Public Health Agency' (2009) 360 N Engl J Med 2493, 2494.
83. WA Ray and M Stein, 'Reform of Drug Regulation-Beyond an Independent Drug-Safety Board' (2006) 354 N Engl J Med 194.
84. EMA Road Map, above, n 68.
85. Eichler and others, above, n 69.
86. F Pignatti and others, 'The European Medicines Agency: An Overview of its Mission, Responsibilities, and Recent Initiatives in Cancer Drug Regulation' (2011) 17 Clin Caner Res 5220.
87. Eichler and others, above, n 69, 429.
88. TM Mulvey, 'Preserving Evidence-Based Oncology: We Can't Jeopardize Clinical Trials' (2006) 2 J Oncol Pract 204. Off-label use may be essential for learning about the use of a drug in combination therapy. According to Mulvey, anywhere from 50% to 80% of cancer chemotherapy involves at least one off-label use of approved drugs.
89. ISPOR Report, above, n 70.
90. Department of Health, 'A new value-based approach to the pricing of branded medicines A consultation' (16 December 2012) accessed 10 March 2014 at 13.
91. Eichler and others, above, n 69.
92. European Medicines Agency, 'Risk-management plans' (August 2013) accessed 10 March 2014.
93. Owen and others, above, n 77, 236.
94. Organisation for Professionals in Regulatory Affairs (TOPRA), 'Can adaptive licensing bridge the gap between regulatory and HTA evidentiary standards?' (3 December 2012) accessed 10 March 2014.
95. J Lexchin, 'Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications' (2010) 18 Sci Eng Ethics 247.
96. See Lemmens, above, n 60.
97. See discussions in T Lemmens and C Telfer, 'Access to Information and the Right to Health: The Human Rights Case for Clinical Trials Transparency' (2011) 38 Am J Law Med 63.
98. See also Lemmens, above, n 60.
99. AJ London, J Kimmelman, and ME Emborg, 'Beyond Access vs Protection in Trials of Innovative Therapies' (2010) 328 Science 829.
100. See also J Kimmelman and AJ London, 'Predicting Harms and Benefits in Translational Trials:Ethics, Evidence and Uncertainty' (2011) 8 PLoS Med e10001010;
101. J Kimmelman and JA Anderson, 'Should Pre-clinical Research be Registered' (2012) 30 Nat Biotech 488.
102. D Healy, Pharmageddon (University of California Press, Los Angeles 2012).
103. European Medicines Agency, '2010 pharmacovigilance legislation' accessed 10 March 2014.
104. European Medicines Agency, 'European Medicines Agency policy on access to documents (related to medicinal products for human and veterinary use) (Policy/0043)' (30 November 2010) accessed 10 March 2014.
105. Case T-44/13 Order of the President of the General Court of 29 April 2013-AbbVie v EMA OJ 2013/C 189/51;
106. Case T-73/13 R Order of the President of the General Court of 25 April 2013-InterMune UK and Others v EMA OJ 2013/C 189/52.
107. Lemmens, above, n 60.
108. Case C-389/13 P(R) Order of the Vice-President of the Court of 28 November 2013-AbbVie v EMA OJ 2013/C 189/51;
109. Case C-390/13 P(R) Order of the Vice-President of the Court of 28 November 2013-InterMune UK and Others v EMA OJ 2013/C 189/52.
110. Z Fiminska, 'Abbvie Move Against Data Transparency' eye for pharma (12 March 2013) accessed 10 March 2014.
111. European Medicines Agency, 'Publication and access to clinical-trial data (Policy/0070-draft for public consultation) (24 June 2013) accessed 10 March 2014.
112. There is growing concern about the potential for industry to hijack advocacy groups as a vehicle in their own lobbying efforts. See, for example, D Hughes and B Williams-Jones, 'Coalition Priorité Cancer and the Pharmaceutical Industry in Quebec: Conflicts of Interest in the Reimbursement of Expensive cancer Drugs?' (2013) 9 (1) Healthcare Policy 52.
113. D Bishop and J Lexchin, 'Politics and its Intersection with Coverage with Evidence Development: a Qualitative Analysis from Expert Interviews' (2013) 13(88) BMC Health Serv Res, doi: 10.1186/1472-6963-13-88.
114. Owen and others, above, n 77, 236.
115. J Raftery, 'Multiple Sclerosis Risk Sharing Scheme: A Costly Failure' (2010) 340 Brit Med J 1282.
116. Bishop and Lexchin, above, n 117, 7.
117. Health Action International Europe and Corporate Europe Observatory, 'Divide & Conquer: A look behind the scenes of the EU pharmaceutical industry lobby' (March 2012) accessed 10 March 2014.
118. L Garrison, 'Performance-based Risk-sharing Arrangements: Good Practices for Design, Implementation and Evaluation' (Report Presented at 7th Annual ISPOR Meeting Washington D.C. 2012) (2012) accessed 10 March 2014.
119. Raftery, above, n 120.
120. See Multiple-Sclerosis Trust, 'The Risk-Sharing Scheme for Disease Modifying Therapies in MS' (2007) accessed 10 March 2014.
121. Raftery, above, n 120.
122. M Boggild and others, 'Multiple Sclerosis Risk Sharing Scheme: Two Year Results of Clinical Cohort Study with Historical Comparator' (2009) 339 Brit Med J 1355.
123. Raftery, above, n 120.
124. C McCabe and others, 'Continuing the Multiple Sclerosis Risk Sharing Scheme Is Unjustified' (2010) 340 Brit Med J 1786.
125. Multiple Sclerosis Trust, 'A to Z of MS: Risk-sharing Scheme' accessed 10 March 2014.
126. McCabe and others, above, n 130.
127. Raftery, above, n 120, 1284.
128. S Fernando and A Moss, 'UK value-based pricing will struggle to materialise as year-end deadline approaches' Financial Times (13 March 2013) accessed 10 March 2014.